Benefits of Cardiac Rehabilitation in Cardio-Renal Patients With Heart Failure With Reduced Ejection Fraction

Ahmad Mroué1, Stéphane Roueff, Isabella Vanorio-Vega

  • 1Department of Nephrology, Georges Pompidou European Hospital, APHP, Paris, France (Drs Mroué, Roueff, Lazareth, Flahault, and Thervet); Direction de la stratégie des études et des statistiques, Caisse nationale de l'assurance maladie (CNAM), Paris, France (Drs Vanorio-Vega and Tuppin); Agence de la biomédecine, Saint-Denis, France (Dr Vanorio-Vega); Université Paris Cité, Paris, France (Drs Lazareth, Flahault, and Thervet); and Department of Cardiac Rehabilitation and Secondary Prevention, Corentin Celton Hospital, APHP, Paris, France (Drs Kovalska and Iliou).

Insights

Cardiac rehabilitation (CR) improves cardiorespiratory fitness in heart failure (HF) patients with reduced ejection fraction (HFrEF), even those with chronic kidney disease (CKD). CKD stage does not impact the benefits of CR for HFrEF patients.

Area of Science:

  • Cardiology
  • Nephrology
  • Exercise Physiology

Background:

  • Chronic kidney disease (CKD) is prevalent in heart failure (HF) patients, often worsening prognosis and complicating management.
  • CKD is frequently associated with sarcopenia, potentially limiting the efficacy of cardiac rehabilitation (CR).

Purpose of the Study:

  • To assess the impact of CR on cardiorespiratory fitness in heart failure with reduced ejection fraction (HFrEF) patients stratified by CKD stage.
  • To determine if CKD influences the benefits derived from CR in HFrEF.

Main Methods:

  • A retrospective analysis of 567 HFrEF patients undergoing a 4-week CR program.
  • Cardiorespiratory exercise testing was performed pre- and post-CR, with patients stratified by estimated glomerular filtration rate (eGFR).
  • Multivariate analysis identified factors associated with improvements in peak oxygen uptake (V˙ o2peak).

Main Results:

  • 38% of patients had eGFR <60 mL/min/1.73m², showing poorer baseline fitness and higher brain natriuretic peptide levels.
  • Following CR, significant improvements in V˙ o2peak, ventilatory threshold (VT1), workload, and reduced brain natriuretic peptide were observed across all CKD stages.
  • Renal function did not emerge as a significant factor influencing V˙ o2peak improvement post-CR.

Conclusions:

  • Cardiac rehabilitation demonstrates significant benefits for HFrEF patients with CKD, irrespective of the CKD stage.
  • The presence of CKD should not be a contraindication for prescribing CR to HFrEF patients.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
479
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
18
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
435
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
20
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
894